tuneTypical Dose
Common supplemental range in joint-support use
Chemical Compound
MSM
Methylsulfonylmethane
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Symptom changes take weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
MSM may modestly improve knee symptoms and quality of life, but the effect is small and still much weaker than joint-supplement marketing suggests.
MSM has a real but limited evidence base for symptom relief in knee osteoarthritis and mild knee pain. The signal is consistent enough to take seriously, but the effect size remains modest and systematic reviews still question how clinically meaningful it is for most users. That makes MSM a low- to moderate-confidence symptom supplement, not a disease-modifying joint therapy.
MSM is proposed to influence inflammatory and oxidative pathways, but the human evidence supports only modest symptom improvement rather than strong disease modification.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Small improvement in knee osteoarthritis symptoms
Secondary Outcomes
- No proven disease-modifying benefit
Safety
Contraindications and Interactions
Contraindications
No entries provided
Side effects
- Mild GI upset
Interactions
No entries provided
Avoid if
- You are using it instead of evidence-based arthritis care
Evidence
Study-level References
msm-SRC-001Randomized controlled trial
Sourceopen_in_newDebbi EM, et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. BMC Complement Altern Med. 2011;11:50. doi:10.1186/1472-6882-11-50. PMID:21708034.
Population: Adults with knee osteoarthritis.
Dose protocol: 1.125 g three times daily for 12 weeks
Key findings: Small improvements in OA pain and function versus placebo.
Notes: Main direct RCT.
Paper content
This is the main direct MSM knee-OA trial. It supports small symptom improvement, but the effect size is modest and not practice changing.
msm-SRC-002Systematic review and meta-analysis
Sourceopen_in_newBrien S, et al. Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Rheumatology (Oxford). 2009;48(9):126-131. doi:10.1093/rheumatology/kep129. PMID:19474240.
Population: Adults with osteoarthritis of the knee.
Dose protocol: MSM and DMSO trials in knee OA
Key findings: Limited overall clinical effectiveness.
Notes: Best limit-setting review.
Paper content
This review tempers the MSM story. The overall clinical effect in OA appears small and not clearly clinically meaningful.
msm-SRC-003Randomized, double-blind, placebo-controlled trial
Sourceopen_in_newToguchi A, Noguchi N, Kanno T, Yamada A. Methylsulfonylmethane improves knee quality of life in participants with mild knee pain. A randomized, double-blind, placebo-controlled trial. Nutrients. 2023;15(13):2995. doi:10.3390/nu15132995. PMID:37447322.
Population: Healthy Japanese adults with mild knee pain.
Dose protocol: 2 g daily for 12 weeks in adults with mild knee pain
Key findings: Small but statistically significant improvement in JKOM total score and knee-related quality of life versus placebo.
Notes: Useful modern confirmation that any benefit remains modest even outside established osteoarthritis.
Paper content
This 12-week placebo-controlled trial in adults with mild knee pain found a small but statistically significant improvement in total JKOM score and knee-related quality-of-life measures with 2 g/day of MSM. It supports a symptom-level benefit outside established osteoarthritis, but the effect size was modest and the population had mild baseline symptoms rather than clinically significant OA.